Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
19 Apr 24
8-K
Material Modifications to Rights of Security Holders
19 Apr 24
10-K
2023 FY
Annual report
22 Mar 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
424B4
Prospectus supplement with pricing info
2 Oct 23
EFFECT
Notice of effectiveness
2 Oct 23
CORRESP
Correspondence with SEC
28 Sep 23
S-1/A
IPO registration (amended)
26 Sep 23
UPLOAD
Letter from SEC
26 Sep 23
CORRESP
Correspondence with SEC
20 Sep 23
S-1
IPO registration
19 Sep 23
8-K
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
24 Aug 23
EFFECT
Notice of effectiveness
15 Aug 23
424B4
Prospectus supplement with pricing info
14 Aug 23
CORRESP
Correspondence with SEC
10 Aug 23
S-1/A
IPO registration (amended)
8 Aug 23
S-1/A
IPO registration (amended)
2 Aug 23
10-Q
2023 Q2
Quarterly report
31 Jul 23
S-1/A
IPO registration (amended)
12 Jul 23
UPLOAD
Letter from SEC
12 Jul 23
S-1/A
IPO registration (amended)
7 Jul 23
UPLOAD
Letter from SEC
6 Jul 23
S-1/A
IPO registration (amended)
30 Jun 23
UPLOAD
Letter from SEC
29 Jun 23
S-1
IPO registration
16 Jun 23
8-K
Entry into a Material Definitive Agreement
12 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
31 Mar 23
D
$6.00 mm in equity / debt, sold $130.00 k, 3 investors
13 Mar 23
8-K
Changes in Registrant's Certifying Accountant
7 Mar 23
RW
Registration withdrawal request
2 Mar 23
8-K
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
6 Feb 23
8-K
Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization
14 Dec 22
8-K
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
8 Dec 22
8-K
Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print
16 Nov 22
8-K
Entry into a Material Definitive Agreement
14 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
RW
Registration withdrawal request
22 Sep 22
RW WD
Withdrawal of registration withdrawal request
21 Sep 22
Latest ownership filings
4
RADKA MILANOVA
19 Apr 24
4
DALE H CONAWAY
19 Apr 24
4
Alan M Hoberman
19 Apr 24
3
RADKA MILANOVA
19 Apr 24
4
Anders Utter
27 Mar 24
4
DALE H CONAWAY
27 Mar 24
4
DAVID PLATT
27 Mar 24
4
Alan M Hoberman
27 Mar 24
5
Anders Utter
16 Jan 24
5
DALE H CONAWAY
16 Jan 24
5
Alan M Hoberman
16 Jan 24
4
DAVID PLATT
16 Jan 24
5
Hana Chen-Walden
16 Jan 24
4
DALE H CONAWAY
2 Nov 23
4
Anders Utter
2 Nov 23
4
Alan M Hoberman
2 Nov 23
4
Hana Chen-Walden
10 Oct 23
4
DAVID PLATT
15 Sep 23
4
DAVID PLATT
24 Aug 23
4
DALE H CONAWAY
24 Aug 23
4
Anders Utter
24 Aug 23
4
Alan M Hoberman
24 Aug 23
4
Hana Chen-Walden
24 Aug 23
4
DAVID PLATT
17 May 23
4
Ola Soderquist
17 May 23
4
Michael Sheikh
17 May 23
4
DAVID PLATT
10 May 23
4
DALE H CONAWAY
4 May 23
4
Anders Utter
4 May 23
4
Hana Chen-Walden
4 May 23
4
Alan M Hoberman
4 May 23
4
DAVID PLATT
8 Feb 23
5
DAVID PLATT
8 Feb 23
5
Michael Sheikh
8 Feb 23
5
Ola Soderquist
8 Feb 23
5
Hana Chen-Walden
8 Feb 23
5
DALE H CONAWAY
7 Feb 23
5
Anders Utter
7 Feb 23
5
Alan M Hoberman
7 Feb 23
SC 13D/A
OFFER BINDER
16 Aug 22